Previous studies have described TAAs that are expressed in a high proportion of cancer patients; these include MART-1 and gp100 in patients with melanoma and several cancer/testis antigens and NY-ESO-1 and MAGE-A3 expressed in a variety of cancer types 69. This evidence concerns the gene MAGEA3 and cancer.